Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In this review, the pharmacokinetic rationale for hepatic arterial drug therapy is discussed, along with techniques that have been developed in order to try to enhance the regional advantage accrued from this route of administration. Clinical trials of hepatic arterial therapy in patients with primary hepatocellular carcinoma and with liver metastases from colorectal carcinoma are discussed. Although clinical response rates are significantly better with regional as compared with systemic therapy, survival is not prolonged. This is mainly due to the development of extrahepatic metastases. A treatment strategy using high dose hepatic arterial 5-fluorouracil (5-FU) infusion with the deliberate aim of achieving maximum tolerated systemic drug levels has entered phase III clinical trial. Monitoring of in vivo tumour pharmacokinetics using 19F magnetic resonance spectroscopy and 18F-5-FU positron emission tomography (PET) demonstrate elegantly how target drug uptake may be assessed. We plan to use PET to monitor intra-tumoral viral transduction and 5-flucytosine conversion rates to active 5-FU in our hepatic arterial pro-drug gene therapy programme soon to enter clinical trial.

Original publication

DOI

10.3109/10611869608996825

Type

Journal article

Journal

J Drug Target

Publication Date

1996

Volume

3

Pages

341 - 347

Keywords

Antimetabolites, Antineoplastic, Carcinoma, Hepatocellular, Clinical Trials, Phase III as Topic, Colorectal Neoplasms, Fluorouracil, Genetic Therapy, Hepatic Artery, Humans, Infusions, Intra-Arterial, Isotope Labeling, Liver Neoplasms, Magnetic Resonance Spectroscopy, Tomography, Emission-Computed